每經AI快訊，4月29日，珍寶島（603567.SH）發布2024年報，公(gong)(gong)司營(ying)收(shou)27.04億元，實現歸屬于上(shang)市(shi)公(gong)(gong)司股東(dong)凈利(li)潤4.38億元，醫藥(yao)(yao)(yao)工業(ye)營(ying)收(shou)同(tong)比增長20.23%。公(gong)(gong)司表(biao)示，得益于深化(hua)(hua)營(ying)銷(xiao)渠道改(gai)革(ge)，產(chan)(chan)品(pin)市(shi)場覆蓋率(lv)和產(chan)(chan)品(pin)競爭力(li)顯(xian)著(zhu)提升(sheng)。報告期內，公(gong)(gong)司中藥(yao)(yao)(yao)材產(chan)(chan)業(ye)板(ban)塊穩中有進(jin)，“神(shen)農洲”中藥(yao)(yao)(yao)材電商(shang)平臺與線下藥(yao)(yao)(yao)市(shi)協同(tong)互補；新(xin)藥(yao)(yao)(yao)研發及產(chan)(chan)品(pin)銷(xiao)售(shou)進(jin)展順利(li)；公(gong)(gong)司1.1類創新(xin)中藥(yao)(yao)(yao)清降(jiang)和胃顆(ke)粒(li)臨床試(shi)驗(yan)獲批準，枸櫞酸托法(fa)替布片等10款優質(zhi)仿制藥(yao)(yao)(yao)獲批上(shang)市(shi)；通(tong)過深化(hua)(hua)精(jing)細化(hua)(hua)招商(shang)模式(shi)，實現市(shi)場的(de)“廣深透”覆蓋，以終端為(wei)單(dan)位拉動產(chan)(chan)品(pin)上(shang)量。